UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of June 2023

 

Commission File Number: 001-39131

 

LIMINAL BIOSCIENCES INC.

(Translation of registrant’s name into English)

 

 

440 Armand-Frappier Boulevard, Suite 300

Laval, Québec

H7V 4B4

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: ☒ Form 20-F ☐ Form 40-F

 

INCORPORATION BY REFERENCE

 

This Report on Form 6-K (the “Report”) and Exhibits 99.1 and 99.2 to this Report are hereby expressly incorporated by reference into the registrant’s registration statements on Form F-3 (File nos. 333-251055, 333-245703 and 333-251065) filed with the Securities and Exchange Commission on December 1, 2020, December 2, 2020 and December 2, 2020, respectively, and the registration statement on Form S-8 (File no. 333-235692) filed with the Securities and Exchange Commission on December 23, 2019.

 

 

 

EXHIBIT LIST

 

Exhibit

Description

 99.1

 

Press Release dated June 5, 2023

 99.2

 

Report of Voting Results following the AGM held on June 5, 2023

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Liminal BioSciences Inc.

 

 

 

 

Date: June 5, 2023

 

By:

/s/ Bruce Pritchard

 

 

 

Name

Bruce Pritchard

 

 

 

Title:

Chief Executive Officer

 

 
Grafico Azioni Liminal BioSciences (NASDAQ:LMNL)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Liminal BioSciences
Grafico Azioni Liminal BioSciences (NASDAQ:LMNL)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Liminal BioSciences